Opal Capital LLC Grows Stake in Merck & Co., Inc. $MRK

Opal Capital LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 321.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,928 shares of the company’s stock after acquiring an additional 9,098 shares during the period. Opal Capital LLC’s holdings in Merck & Co., Inc. were worth $1,435,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. D.A. Davidson & CO. increased its holdings in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after buying an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC raised its position in Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after acquiring an additional 32,114 shares during the period. Norris Perne & French LLP MI boosted its stake in shares of Merck & Co., Inc. by 12.8% during the 4th quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock worth $26,543,000 after acquiring an additional 28,635 shares during the last quarter. Pinnbrook Capital Management LP grew its position in shares of Merck & Co., Inc. by 95.2% during the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after acquiring an additional 11,355 shares during the period. Finally, Cibc World Market Inc. grew its position in shares of Merck & Co., Inc. by 32.6% during the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock valued at $137,022,000 after acquiring an additional 320,143 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.8%

Shares of MRK stock opened at $131.85 on Wednesday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a fifty day simple moving average of $122.39 and a two-hundred day simple moving average of $118.10. The firm has a market capitalization of $325.64 billion, a PE ratio of 37.14, a PEG ratio of 5.19 and a beta of 0.19. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported that KEYTRUDA met the primary progression-free-survival endpoint in the Phase 3 KEYNOTE-C93 trial for advanced or recurrent endometrial cancer. The result represents a statistically significant benefit over platinum chemotherapy and could support future regulatory filings, strengthening the company’s oncology pipeline. Merck Says KEYTRUDA Beat Chemotherapy in Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Merck is expanding its growth opportunities beyond KEYTRUDA. A royalty-free licensing agreement will enable generic HIV-prevention treatment supply across 129 low- and middle-income countries, while U.S. approval of LIPFENDRA, described as the first oral PCSK9 inhibitor for LDL reduction, broadens its cardiovascular portfolio. Merck Expands HIV PrEP Access and Launches Oral Cholesterol Drug
• Positive Sentiment: Wells Fargo maintained its Buy rating on MRK, signaling continued confidence in the company’s outlook despite near-term earnings pressure. Wells Fargo Sticks to Its Buy Rating for Merck
• Neutral Sentiment: Brokerage firms collectively assigned Merck an average “Moderate Buy” rating, indicating constructive sentiment but not a unanimous expectation of strong upside. Merck Given Average Moderate Buy Rating by Brokerages
• Negative Sentiment: Analysts expect Merck’s upcoming second-quarter earnings to decline, and previews indicate the company may lack the earnings and revenue momentum typically associated with a likely consensus beat. This could limit near-term gains ahead of the report. Merck Q2 Earnings Expected to Decline

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Citigroup started coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Finally, Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.